Upstream Bio (UPB) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $3.37, -1.46% vs the prior close of $3.42.
- Volume 1.29M shares, 1.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
UPB dips 1.5% to $3.37, a 52-week low, 4 down days in a row. Closed at $3.37, -1.46% vs the prior close of $3.42. Day range $3.29–$3.56, opened at $3.44.
UPB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — UPB dips 1.5% to $3.37, a 52-week low, 4 down days in a row
- Closed at $3.37, -1.46% vs the prior close of $3.42. Day range $3.29–$3.56, opened at $3.44.
- Volume was 1.29M shares, 1.7x its 50-day average of 735.01K.
- Price is -42.3% vs its 50-day average ($5.84) and -68.5% vs its 200-day average ($10.69).
- 52-week range $3.29–$33.68; today's close sits at 0% of that range, 90.0% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — UPB slides 3.7% to $3.42, a 52-week low on 2.2x normal volume
- Closed at $3.42, -3.66% vs the prior close of $3.55. Day range $3.29–$3.60, opened at $3.47.
- Volume was 1.57M shares, 2.2x its 50-day average of 730.81K — unusually heavy trading.
- Price is -42.1% vs its 50-day average ($5.91) and -68.4% vs its 200-day average ($10.82).
- 52-week range $3.29–$33.68; today's close sits at 0% of that range, 89.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — UPB slides 14.9% to $3.55, a 52-week low
- Closed at $3.55, -14.87% vs the prior close of $4.17. Day range $3.52–$4.16, opened at $4.14.
- Volume was 1.04M shares, 1.4x its 50-day average of 725.55K.
- Price is -40.6% vs its 50-day average ($5.98) and -67.6% vs its 200-day average ($10.95).
- 52-week range $3.52–$33.68; today's close sits at 0% of that range, 89.5% below the 52-week high.
Oct 12, 2026 — UPB slides 11.3% to $4.17, a 52-week low
- Closed at $4.17, -11.28% vs the prior close of $4.70. Day range $4.12–$4.72, opened at $4.68.
- Volume was 848.40K shares, 1.2x its 50-day average of 714.54K.
- Price is -30.9% vs its 50-day average ($6.03) and -62.4% vs its 200-day average ($11.08).
- 52-week range $4.12–$33.68; today's close sits at 0% of that range, 87.6% below the 52-week high.
Oct 9, 2026 — UPB jumps 3.3% to $4.70
- Closed at $4.70, +3.30% vs the prior close of $4.55. Day range $4.51–$4.76, opened at $4.54.
- Volume was 1.19M shares, 1.7x its 50-day average of 697.19K.
- Price is -22.7% vs its 50-day average ($6.08) and -58.1% vs its 200-day average ($11.21).
- 52-week range $4.36–$33.68; today's close sits at 1% of that range, 86.0% below the 52-week high.
Oct 8, 2026 — UPB dips 1.3% to $4.55, a 52-week low on 4.4x normal volume
- Closed at $4.55, -1.30% vs the prior close of $4.61. Day range $4.36–$4.65, opened at $4.53.
- Volume was 2.86M shares, 4.4x its 50-day average of 654.11K — unusually heavy trading.
- Price is -25.6% vs its 50-day average ($6.12) and -59.9% vs its 200-day average ($11.34).
- 52-week range $4.36–$33.68; today's close sits at 1% of that range, 86.5% below the 52-week high.
Oct 7, 2026 — UPB rises 0.4% to $4.61
- Closed at $4.61, +0.44% vs the prior close of $4.59. Day range $4.50–$4.72, opened at $4.55.
- Volume was 908.40K shares, 1.4x its 50-day average of 644.60K.
- Price is -25.1% vs its 50-day average ($6.15) and -59.8% vs its 200-day average ($11.46).
- 52-week range $4.50–$33.68; today's close sits at 0% of that range, 86.3% below the 52-week high.
Oct 6, 2026 — UPB slides 5.4% to $4.59, a 52-week low, 4 down days in a row
- Closed at $4.59, -5.36% vs the prior close of $4.85. Day range $4.53–$4.86, opened at $4.84.
- Volume was 1.06M shares, 1.7x its 50-day average of 632.55K.
- Price is -25.8% vs its 50-day average ($6.19) and -60.4% vs its 200-day average ($11.59).
- 52-week range $4.53–$33.68; today's close sits at 0% of that range, 86.4% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — UPB slides 3.8% to $4.85, a 52-week low, 3 down days in a row
- Closed at $4.85, -3.77% vs the prior close of $5.04. Day range $4.66–$5.10, opened at $5.07.
- Volume was 1.01M shares, 1.6x its 50-day average of 624.86K.
- Price is -22.1% vs its 50-day average ($6.22) and -58.6% vs its 200-day average ($11.71).
- 52-week range $4.66–$33.68; today's close sits at 1% of that range, 85.6% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — UPB ends flat (+0.0%) to $5.04
- Closed at $5.04, +0.00% vs the prior close of $5.04. Day range $4.86–$5.21, opened at $5.12.
- Volume was 956.50K shares, 1.5x its 50-day average of 618.25K.
- Price is -19.4% vs its 50-day average ($6.26) and -57.4% vs its 200-day average ($11.83).
- 52-week range $4.86–$33.68; today's close sits at 1% of that range, 85.0% below the 52-week high.
UPB latest news & SEC filings
Every SEC filing by or about UPB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gray Michael sold 853 shares at $5.49 (≈$4.68K) on Sep 16, 2026; now holds 27,942
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ambrose Allison sold 485 shares at $5.49 (≈$2.66K) on Sep 16, 2026; now holds 15,563
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Deykin Aaron sold 895 shares at $5.49 (≈$4.91K) on Sep 16, 2026; now holds 32,302
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sutherland Everett Rand sold 2,095 shares at $5.49 (≈$11.50K) on Sep 16, 2026; now holds 68,717
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Houghton Adam sold 700 shares at $5.49 (≈$3.84K) on Sep 16, 2026; now holds 22,901
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $773.00K (prior year $937.00K) (-17.5% vs Jun 30, 2025)
- Net income: -$39.70M (prior year -$39.97M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.73 (prior year -$0.74) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade UPB
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 26, 2026, Feb 11, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.37% (largest 14.9%). That is a volatile stock.
- Liquidity: about 954.19K shares (≈$3.22M) trade per day on average.
- 52-week position: $3.37 vs a range of $3.29–$33.68 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 15 sales; latest: Everett Rand Sutherland sold 2,095 shares on Sep 16, 2026.
- Latest filings: 8-K Sep 1, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 54.77M shares outstanding (Aug 4, 2026), +1.6% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
UPB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 3.44 | 3.56 | 3.29 | 3.37 | 1.29M |
| Oct 14, 2026 | 3.47 | 3.60 | 3.29 | 3.42 | 1.57M |
| Oct 13, 2026 | 4.14 | 4.16 | 3.52 | 3.55 | 1.04M |
| Oct 12, 2026 | 4.68 | 4.72 | 4.12 | 4.17 | 848.40K |
| Oct 9, 2026 | 4.54 | 4.76 | 4.51 | 4.70 | 1.19M |
| Oct 8, 2026 | 4.53 | 4.65 | 4.36 | 4.55 | 2.86M |
| Oct 7, 2026 | 4.55 | 4.72 | 4.50 | 4.61 | 908.40K |
| Oct 6, 2026 | 4.84 | 4.86 | 4.53 | 4.59 | 1.06M |
| Oct 5, 2026 | 5.07 | 5.10 | 4.66 | 4.85 | 1.01M |
| Oct 2, 2026 | 5.12 | 5.21 | 4.86 | 5.04 | 956.50K |
| Oct 1, 2026 | 5.25 | 5.34 | 4.98 | 5.04 | 832.40K |
| Sep 30, 2026 | 5.23 | 5.45 | 5.14 | 5.27 | 851.20K |
| Sep 29, 2026 | 5.28 | 5.30 | 4.99 | 5.19 | 784.20K |
| Sep 28, 2026 | 5.34 | 5.39 | 5.12 | 5.30 | 615.40K |
| Sep 25, 2026 | 5.20 | 5.39 | 5.07 | 5.36 | 429.20K |
| Sep 24, 2026 | 5.19 | 5.20 | 5.05 | 5.17 | 566.60K |
| Sep 23, 2026 | 5.48 | 5.49 | 4.99 | 5.19 | 553.00K |
| Sep 22, 2026 | 5.44 | 5.56 | 5.38 | 5.49 | 360.40K |
| Sep 21, 2026 | 5.42 | 5.44 | 5.27 | 5.36 | 364.00K |
| Sep 18, 2026 | 5.32 | 5.41 | 5.21 | 5.34 | 1.00M |
About Upstream Bio
Upstream Bio (UPB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2022626.
UPB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Daniella Beckman | Director | Jun 11, 2026 |
| Erez Chimovits | Director | Jun 11, 2026 |
| Harold Edward Fleming | Director | Jun 11, 2026 |
| Liam Ratcliffe | Director | Jun 11, 2026 |
| Ronald C Jr Renaud | Director | Jun 11, 2026 |
| Marcella K. Ruddy | Director | Jun 11, 2026 |
| Everett Rand Sutherland | Chief Executive Officer | Sep 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Allison Ambrose | General Counsel | Sep 17, 2026 |
| Aaron Deykin | Chief Medical Officer | Sep 17, 2026 |
| Michael Gray | CFO and COO | Sep 17, 2026 |
| Adam Houghton | Chief Business Officer | Sep 17, 2026 |
| Everett Rand Sutherland | Chief Executive Officer | Sep 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Everett Rand Sutherland | Sale | 2,095 | $5.49 |
| Sep 16, 2026 | Aaron Deykin | Sale | 895 | $5.49 |
| Sep 16, 2026 | Allison Ambrose | Sale | 485 | $5.49 |
| Sep 16, 2026 | Michael Gray | Sale | 853 | $5.49 |
| Sep 16, 2026 | Adam Houghton | Sale | 700 | $5.49 |
| Jun 16, 2026 | Everett Rand Sutherland | Sale | 2,095 | $6.10 |
| Jun 16, 2026 | Adam Houghton | Sale | 700 | $6.10 |
| Jun 16, 2026 | Allison Ambrose | Sale | 477 | $6.10 |
| Jun 16, 2026 | Aaron Deykin | Sale | 895 | $6.10 |
| Jun 16, 2026 | Michael Gray | Sale | 853 | $6.10 |
| Mar 16, 2026 | Allison Ambrose | Sale | 475 | $9.29 |
| Mar 16, 2026 | Adam Houghton | Sale | 699 | $9.29 |
| Mar 16, 2026 | Michael Gray | Sale | 852 | $9.29 |
| Mar 16, 2026 | Aaron Deykin | Sale | 894 | $9.29 |
| Mar 16, 2026 | Everett Rand Sutherland | Sale | 2,093 | $9.29 |
UPB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.85M | $-143.44M | -2.66 | $-133.28M |
| Dec 31, 2024 | $2.37M | $-62.81M | -5.58 | $-59.17M |
| Dec 31, 2023 | $2.38M | $-20.54M | -12.95 | $-37.93M |
Latest balance sheet: total assets $281.17M, total liabilities $10.21M, cash $79.40M (as of Jun 30, 2026).
UPB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $7.09 |
| May 13, 2026 | 8-K Item 2.02 (results) | $9.36 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $9.79 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $14.69 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $23.97 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $16.72 |
| May 6, 2025 | 8-K Item 2.02 (results) | $8.21 |
| Mar 12, 2025 | 8-K Item 2.02 (results) | $9.23 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $27.02 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on UPB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.